nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—ADA—C-MYB transcription factor network—MYF6—muscle cancer	0.0278	0.128	CbGpPWpGaD
Vidarabine—DPP4—embryo—muscle cancer	0.0244	0.0631	CbGeAlD
Vidarabine—ADA—renal system—muscle cancer	0.0233	0.0603	CbGeAlD
Vidarabine—ADK—smooth muscle tissue—muscle cancer	0.0198	0.0512	CbGeAlD
Vidarabine—DPP4—smooth muscle tissue—muscle cancer	0.0192	0.0496	CbGeAlD
Vidarabine—ADK—renal system—muscle cancer	0.0191	0.0493	CbGeAlD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—TP63—muscle cancer	0.0186	0.0856	CbGpPWpGaD
Vidarabine—DPP4—renal system—muscle cancer	0.0185	0.0477	CbGeAlD
Vidarabine—ADA—tendon—muscle cancer	0.0182	0.0471	CbGeAlD
Vidarabine—ADA—bone marrow—muscle cancer	0.0176	0.0456	CbGeAlD
Vidarabine—ADK—cardiac atrium—muscle cancer	0.0171	0.0441	CbGeAlD
Vidarabine—ADA—vagina—muscle cancer	0.0169	0.0437	CbGeAlD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—TP63—muscle cancer	0.0166	0.0766	CbGpPWpGaD
Vidarabine—Coronary artery disease—Vincristine—muscle cancer	0.0165	0.0416	CcSEcCtD
Vidarabine—ADA—head—muscle cancer	0.0156	0.0403	CbGeAlD
Vidarabine—ADA—testis—muscle cancer	0.0151	0.039	CbGeAlD
Vidarabine—ADK—tendon—muscle cancer	0.0149	0.0384	CbGeAlD
Vidarabine—DPP4—tendon—muscle cancer	0.0144	0.0373	CbGeAlD
Vidarabine—ADK—bone marrow—muscle cancer	0.0144	0.0372	CbGeAlD
Vidarabine—ADA—p73 transcription factor network—TP73—muscle cancer	0.0143	0.0657	CbGpPWpGaD
Vidarabine—ADORA2A—head—muscle cancer	0.0142	0.0367	CbGeAlD
Vidarabine—DPP4—bone marrow—muscle cancer	0.014	0.0361	CbGeAlD
Vidarabine—ADK—vagina—muscle cancer	0.0138	0.0357	CbGeAlD
Vidarabine—ADORA2A—testis—muscle cancer	0.0137	0.0354	CbGeAlD
Vidarabine—DPP4—vagina—muscle cancer	0.0134	0.0346	CbGeAlD
Vidarabine—ADK—head—muscle cancer	0.0128	0.033	CbGeAlD
Vidarabine—DPP4—head—muscle cancer	0.0124	0.0319	CbGeAlD
Vidarabine—ADK—testis—muscle cancer	0.0123	0.0318	CbGeAlD
Vidarabine—ADA—p73 transcription factor network—TP63—muscle cancer	0.0123	0.0565	CbGpPWpGaD
Vidarabine—Electrocardiogram ST segment depression—Doxorubicin—muscle cancer	0.012	0.0305	CcSEcCtD
Vidarabine—DPP4—testis—muscle cancer	0.0119	0.0309	CbGeAlD
Vidarabine—ADA—C-MYB transcription factor network—MYOD1—muscle cancer	0.0111	0.051	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—CD34—muscle cancer	0.0111	0.051	CbGpPWpGaD
Vidarabine—ADA—p73 transcription factor network—WT1—muscle cancer	0.0108	0.0498	CbGpPWpGaD
Vidarabine—Throat tightness—Etoposide—muscle cancer	0.0108	0.0272	CcSEcCtD
Vidarabine—Taste metallic—Methotrexate—muscle cancer	0.00994	0.0251	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—TIMM10—muscle cancer	0.00824	0.0379	CbGpPWpGaD
Vidarabine—Numbness—Vincristine—muscle cancer	0.00785	0.0199	CcSEcCtD
Vidarabine—Sensory loss—Vincristine—muscle cancer	0.00752	0.019	CcSEcCtD
Vidarabine—Supraventricular extrasystoles—Doxorubicin—muscle cancer	0.00734	0.0186	CcSEcCtD
Vidarabine—Sinus tachycardia—Doxorubicin—muscle cancer	0.00679	0.0172	CcSEcCtD
Vidarabine—Respiratory failure—Vincristine—muscle cancer	0.00663	0.0168	CcSEcCtD
Vidarabine—Tingling sensation—Etoposide—muscle cancer	0.00656	0.0166	CcSEcCtD
Vidarabine—Numbness—Etoposide—muscle cancer	0.00636	0.0161	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIDINS220—muscle cancer	0.00624	0.0287	CbGpPWpGaD
Vidarabine—Apnoea—Etoposide—muscle cancer	0.00622	0.0157	CcSEcCtD
Vidarabine—Sensory loss—Etoposide—muscle cancer	0.00609	0.0154	CcSEcCtD
Vidarabine—Chest discomfort—Etoposide—muscle cancer	0.00596	0.0151	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—muscle cancer	0.00548	0.0252	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—MDM2—muscle cancer	0.00531	0.0245	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—muscle cancer	0.0049	0.0226	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KIDINS220—muscle cancer	0.0048	0.0221	CbGpPWpGaD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—MDM2—muscle cancer	0.00475	0.0219	CbGpPWpGaD
Vidarabine—Burning sensation—Methotrexate—muscle cancer	0.00455	0.0115	CcSEcCtD
Vidarabine—Cardiac arrest—Vincristine—muscle cancer	0.00449	0.0114	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—KIT—muscle cancer	0.00424	0.0195	CbGpPWpGaD
Vidarabine—ADORA2A—GPCRs, Other—CNR1—muscle cancer	0.00398	0.0183	CbGpPWpGaD
Vidarabine—Hyperventilation—Doxorubicin—muscle cancer	0.00397	0.0101	CcSEcCtD
Vidarabine—Burning sensation—Doxorubicin—muscle cancer	0.00394	0.00996	CcSEcCtD
Vidarabine—Cardiac failure—Etoposide—muscle cancer	0.00392	0.00992	CcSEcCtD
Vidarabine—Apnoea—Methotrexate—muscle cancer	0.00373	0.00942	CcSEcCtD
Vidarabine—Ventricular arrhythmia—Doxorubicin—muscle cancer	0.0037	0.00934	CcSEcCtD
Vidarabine—Cardiac arrest—Etoposide—muscle cancer	0.00364	0.0092	CcSEcCtD
Vidarabine—Scotoma—Doxorubicin—muscle cancer	0.0036	0.00911	CcSEcCtD
Vidarabine—Acute coronary syndrome—Vincristine—muscle cancer	0.00359	0.00908	CcSEcCtD
Vidarabine—Myocardial infarction—Vincristine—muscle cancer	0.00357	0.00903	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—MDM2—muscle cancer	0.00351	0.0161	CbGpPWpGaD
Vidarabine—Sweating—Vincristine—muscle cancer	0.00349	0.00883	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CDKN2A—muscle cancer	0.00344	0.0158	CbGpPWpGaD
Vidarabine—Flushing—Dactinomycin—muscle cancer	0.0034	0.00859	CcSEcCtD
Vidarabine—Bronchospasm—Etoposide—muscle cancer	0.00325	0.00823	CcSEcCtD
Vidarabine—Hypoaesthesia—Vincristine—muscle cancer	0.00325	0.00823	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—PTGS2—muscle cancer	0.00322	0.0148	CbGpPWpGaD
Vidarabine—Respiratory failure—Methotrexate—muscle cancer	0.00322	0.00813	CcSEcCtD
Vidarabine—Cardiac disorder—Vincristine—muscle cancer	0.00303	0.00767	CcSEcCtD
Vidarabine—Ventricular extrasystoles—Doxorubicin—muscle cancer	0.00303	0.00766	CcSEcCtD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—muscle cancer	0.003	0.0138	CbGpPWpGaD
Vidarabine—Mediastinal disorder—Vincristine—muscle cancer	0.00295	0.00745	CcSEcCtD
Vidarabine—Acute coronary syndrome—Etoposide—muscle cancer	0.00291	0.00735	CcSEcCtD
Vidarabine—Myocardial infarction—Etoposide—muscle cancer	0.00289	0.00731	CcSEcCtD
Vidarabine—Atrioventricular block—Doxorubicin—muscle cancer	0.00282	0.00713	CcSEcCtD
Vidarabine—Back pain—Vincristine—muscle cancer	0.00275	0.00696	CcSEcCtD
Vidarabine—Ventricular tachycardia—Doxorubicin—muscle cancer	0.00274	0.00692	CcSEcCtD
Vidarabine—Injection site reaction—Doxorubicin—muscle cancer	0.00272	0.00688	CcSEcCtD
Vidarabine—Discomfort—Dactinomycin—muscle cancer	0.00268	0.00678	CcSEcCtD
Vidarabine—Hypoaesthesia—Etoposide—muscle cancer	0.00264	0.00666	CcSEcCtD
Vidarabine—Agitation—Vincristine—muscle cancer	0.00262	0.00661	CcSEcCtD
Vidarabine—ADK—Metabolism—FH—muscle cancer	0.00254	0.0117	CbGpPWpGaD
Vidarabine—Convulsion—Vincristine—muscle cancer	0.00247	0.00624	CcSEcCtD
Vidarabine—Flushing—Etoposide—muscle cancer	0.00246	0.00622	CcSEcCtD
Vidarabine—Cardiac disorder—Etoposide—muscle cancer	0.00246	0.00622	CcSEcCtD
Vidarabine—Hypertension—Vincristine—muscle cancer	0.00246	0.00621	CcSEcCtD
Vidarabine—Mediastinal disorder—Etoposide—muscle cancer	0.00239	0.00604	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.00237	0.00599	CcSEcCtD
Vidarabine—Cerebrovascular accident—Methotrexate—muscle cancer	0.00234	0.00592	CcSEcCtD
Vidarabine—Anaphylactic shock—Vincristine—muscle cancer	0.00232	0.00587	CcSEcCtD
Vidarabine—Dysgeusia—Etoposide—muscle cancer	0.00226	0.00571	CcSEcCtD
Vidarabine—Hyperhidrosis—Vincristine—muscle cancer	0.00225	0.00568	CcSEcCtD
Vidarabine—Back pain—Etoposide—muscle cancer	0.00223	0.00564	CcSEcCtD
Vidarabine—Pain—Dactinomycin—muscle cancer	0.00222	0.00562	CcSEcCtD
Vidarabine—Mood swings—Methotrexate—muscle cancer	0.00217	0.00549	CcSEcCtD
Vidarabine—Hypotension—Vincristine—muscle cancer	0.00217	0.00549	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Vincristine—muscle cancer	0.00212	0.00535	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.00211	0.00972	CbGpPWpGaD
Vidarabine—Paraesthesia—Vincristine—muscle cancer	0.00209	0.00527	CcSEcCtD
Vidarabine—Cardiac failure—Doxorubicin—muscle cancer	0.00203	0.00514	CcSEcCtD
Vidarabine—Loss of consciousness—Etoposide—muscle cancer	0.00203	0.00512	CcSEcCtD
Vidarabine—Cerebrovascular accident—Doxorubicin—muscle cancer	0.00203	0.00512	CcSEcCtD
Vidarabine—Cough—Etoposide—muscle cancer	0.00201	0.00509	CcSEcCtD
Vidarabine—Convulsion—Etoposide—muscle cancer	0.002	0.00505	CcSEcCtD
Vidarabine—Hypertension—Etoposide—muscle cancer	0.00199	0.00503	CcSEcCtD
Vidarabine—Pain—Vincristine—muscle cancer	0.00199	0.00502	CcSEcCtD
Vidarabine—Chest pain—Etoposide—muscle cancer	0.00196	0.00496	CcSEcCtD
Vidarabine—Affect lability—Doxorubicin—muscle cancer	0.00195	0.00494	CcSEcCtD
Vidarabine—Discomfort—Etoposide—muscle cancer	0.00194	0.0049	CcSEcCtD
Vidarabine—Hypersensitivity—Dactinomycin—muscle cancer	0.00192	0.00484	CcSEcCtD
Vidarabine—Abdominal discomfort—Methotrexate—muscle cancer	0.0019	0.0048	CcSEcCtD
Vidarabine—Cardiac arrest—Doxorubicin—muscle cancer	0.00189	0.00477	CcSEcCtD
Vidarabine—Anaphylactic shock—Etoposide—muscle cancer	0.00188	0.00476	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—muscle cancer	0.00188	0.00476	CcSEcCtD
Vidarabine—Asthenia—Dactinomycin—muscle cancer	0.00187	0.00472	CcSEcCtD
Vidarabine—Tachycardia—Etoposide—muscle cancer	0.00184	0.00464	CcSEcCtD
Vidarabine—Hyperhidrosis—Etoposide—muscle cancer	0.00182	0.0046	CcSEcCtD
Vidarabine—Drowsiness—Methotrexate—muscle cancer	0.00177	0.00447	CcSEcCtD
Vidarabine—Hypotension—Etoposide—muscle cancer	0.00176	0.00445	CcSEcCtD
Vidarabine—ADORA2A—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.00173	0.00796	CbGpPWpGaD
Vidarabine—ADA—Metabolism—FH—muscle cancer	0.00173	0.00796	CbGpPWpGaD
Vidarabine—Hypersensitivity—Vincristine—muscle cancer	0.00171	0.00433	CcSEcCtD
Vidarabine—Sweating—Methotrexate—muscle cancer	0.00169	0.00428	CcSEcCtD
Vidarabine—Paraesthesia—Etoposide—muscle cancer	0.00169	0.00427	CcSEcCtD
Vidarabine—Dyspnoea—Etoposide—muscle cancer	0.00168	0.00424	CcSEcCtD
Vidarabine—Somnolence—Etoposide—muscle cancer	0.00167	0.00423	CcSEcCtD
Vidarabine—Asthenia—Vincristine—muscle cancer	0.00167	0.00421	CcSEcCtD
Vidarabine—Vomiting—Dactinomycin—muscle cancer	0.00165	0.00418	CcSEcCtD
Vidarabine—Rash—Dactinomycin—muscle cancer	0.00164	0.00414	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—FOXO4—muscle cancer	0.00162	0.00747	CbGpPWpGaD
Vidarabine—Pain—Etoposide—muscle cancer	0.00161	0.00407	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—muscle cancer	0.00159	0.00401	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.00156	0.00718	CbGpPWpGaD
Vidarabine—Nausea—Dactinomycin—muscle cancer	0.00154	0.0039	CcSEcCtD
Vidarabine—Dizziness—Vincristine—muscle cancer	0.00154	0.00388	CcSEcCtD
Vidarabine—Drowsiness—Doxorubicin—muscle cancer	0.00153	0.00387	CcSEcCtD
Vidarabine—Urticaria—Etoposide—muscle cancer	0.00149	0.00378	CcSEcCtD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.00148	0.00682	CbGpPWpGaD
Vidarabine—Tinnitus—Methotrexate—muscle cancer	0.00148	0.00374	CcSEcCtD
Vidarabine—Vomiting—Vincristine—muscle cancer	0.00148	0.00373	CcSEcCtD
Vidarabine—Cardiac disorder—Methotrexate—muscle cancer	0.00147	0.00372	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—muscle cancer	0.00147	0.00371	CcSEcCtD
Vidarabine—Rash—Vincristine—muscle cancer	0.00146	0.0037	CcSEcCtD
Vidarabine—Dermatitis—Vincristine—muscle cancer	0.00146	0.0037	CcSEcCtD
Vidarabine—Headache—Vincristine—muscle cancer	0.00146	0.00368	CcSEcCtD
Vidarabine—ADK—Metabolism—MED12—muscle cancer	0.00144	0.00661	CbGpPWpGaD
Vidarabine—Mediastinal disorder—Methotrexate—muscle cancer	0.00143	0.00362	CcSEcCtD
Vidarabine—Bradycardia—Doxorubicin—muscle cancer	0.0014	0.00354	CcSEcCtD
Vidarabine—Hypersensitivity—Etoposide—muscle cancer	0.00139	0.00351	CcSEcCtD
Vidarabine—Nausea—Vincristine—muscle cancer	0.00138	0.00349	CcSEcCtD
Vidarabine—Hypoaesthesia—Doxorubicin—muscle cancer	0.00137	0.00346	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—IGF2—muscle cancer	0.00136	0.00624	CbGpPWpGaD
Vidarabine—Dysgeusia—Methotrexate—muscle cancer	0.00135	0.00342	CcSEcCtD
Vidarabine—Asthenia—Etoposide—muscle cancer	0.00135	0.00341	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—PTCH1—muscle cancer	0.00134	0.00616	CbGpPWpGaD
Vidarabine—Back pain—Methotrexate—muscle cancer	0.00134	0.00338	CcSEcCtD
Vidarabine—ADK—Metabolism—ENO2—muscle cancer	0.00131	0.00603	CbGpPWpGaD
Vidarabine—Vision blurred—Methotrexate—muscle cancer	0.0013	0.00329	CcSEcCtD
Vidarabine—Tinnitus—Doxorubicin—muscle cancer	0.00128	0.00324	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—muscle cancer	0.00127	0.00322	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—muscle cancer	0.00127	0.00322	CcSEcCtD
Vidarabine—Dizziness—Etoposide—muscle cancer	0.00124	0.00315	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—muscle cancer	0.00124	0.00313	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—muscle cancer	0.00123	0.0031	CcSEcCtD
Vidarabine—Cough—Methotrexate—muscle cancer	0.00121	0.00305	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—FOXO1—muscle cancer	0.0012	0.00552	CbGpPWpGaD
Vidarabine—Convulsion—Methotrexate—muscle cancer	0.0012	0.00303	CcSEcCtD
Vidarabine—Vomiting—Etoposide—muscle cancer	0.0012	0.00303	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.00119	0.00547	CbGpPWpGaD
Vidarabine—Rash—Etoposide—muscle cancer	0.00119	0.003	CcSEcCtD
Vidarabine—Dermatitis—Etoposide—muscle cancer	0.00119	0.003	CcSEcCtD
Vidarabine—Headache—Etoposide—muscle cancer	0.00118	0.00298	CcSEcCtD
Vidarabine—Chest pain—Methotrexate—muscle cancer	0.00118	0.00297	CcSEcCtD
Vidarabine—Tension—Doxorubicin—muscle cancer	0.00117	0.00297	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—muscle cancer	0.00117	0.00296	CcSEcCtD
Vidarabine—Discomfort—Methotrexate—muscle cancer	0.00116	0.00294	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—muscle cancer	0.00116	0.00294	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—muscle cancer	0.00116	0.00292	CcSEcCtD
Vidarabine—ADORA2A—GPCR ligand binding—CNR1—muscle cancer	0.00113	0.0052	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Methotrexate—muscle cancer	0.00113	0.00285	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—muscle cancer	0.00113	0.00285	CcSEcCtD
Vidarabine—Nausea—Etoposide—muscle cancer	0.00112	0.00283	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—muscle cancer	0.0011	0.00278	CcSEcCtD
Vidarabine—Hyperhidrosis—Methotrexate—muscle cancer	0.00109	0.00276	CcSEcCtD
Vidarabine—Syncope—Doxorubicin—muscle cancer	0.00107	0.00271	CcSEcCtD
Vidarabine—Palpitations—Doxorubicin—muscle cancer	0.00106	0.00267	CcSEcCtD
Vidarabine—Hypotension—Methotrexate—muscle cancer	0.00105	0.00266	CcSEcCtD
Vidarabine—Loss of consciousness—Doxorubicin—muscle cancer	0.00105	0.00266	CcSEcCtD
Vidarabine—Cough—Doxorubicin—muscle cancer	0.00104	0.00264	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—muscle cancer	0.00104	0.00262	CcSEcCtD
Vidarabine—Hypertension—Doxorubicin—muscle cancer	0.00103	0.00261	CcSEcCtD
Vidarabine—ADORA2A—Signaling Pathways—KIDINS220—muscle cancer	0.00103	0.00474	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.00103	0.0026	CcSEcCtD
Vidarabine—Chest pain—Doxorubicin—muscle cancer	0.00102	0.00257	CcSEcCtD
Vidarabine—Anxiety—Doxorubicin—muscle cancer	0.00101	0.00257	CcSEcCtD
Vidarabine—Paraesthesia—Methotrexate—muscle cancer	0.00101	0.00256	CcSEcCtD
Vidarabine—Discomfort—Doxorubicin—muscle cancer	0.00101	0.00254	CcSEcCtD
Vidarabine—Dyspnoea—Methotrexate—muscle cancer	0.001	0.00254	CcSEcCtD
Vidarabine—Somnolence—Methotrexate—muscle cancer	0.001	0.00253	CcSEcCtD
Vidarabine—Dry mouth—Doxorubicin—muscle cancer	0.000996	0.00252	CcSEcCtD
Vidarabine—ADA—Metabolism—MED12—muscle cancer	0.000977	0.0045	CbGpPWpGaD
Vidarabine—Anaphylactic shock—Doxorubicin—muscle cancer	0.000976	0.00247	CcSEcCtD
Vidarabine—Pain—Methotrexate—muscle cancer	0.000964	0.00244	CcSEcCtD
Vidarabine—Shock—Doxorubicin—muscle cancer	0.00096	0.00243	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—TP53—muscle cancer	0.000953	0.00439	CbGpPWpGaD
Vidarabine—Tachycardia—Doxorubicin—muscle cancer	0.000953	0.00241	CcSEcCtD
Vidarabine—Hyperhidrosis—Doxorubicin—muscle cancer	0.000944	0.00239	CcSEcCtD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	0.000936	0.00431	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KIT—muscle cancer	0.000914	0.0042	CbGpPWpGaD
Vidarabine—Hypotension—Doxorubicin—muscle cancer	0.000912	0.00231	CcSEcCtD
Vidarabine—Urticaria—Methotrexate—muscle cancer	0.000895	0.00226	CcSEcCtD
Vidarabine—ADA—Metabolism—ENO2—muscle cancer	0.000891	0.0041	CbGpPWpGaD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000889	0.00225	CcSEcCtD
Vidarabine—Paraesthesia—Doxorubicin—muscle cancer	0.000876	0.00222	CcSEcCtD
Vidarabine—Dyspnoea—Doxorubicin—muscle cancer	0.00087	0.0022	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—muscle cancer	0.000868	0.00219	CcSEcCtD
Vidarabine—Pain—Doxorubicin—muscle cancer	0.000835	0.00211	CcSEcCtD
Vidarabine—Hypersensitivity—Methotrexate—muscle cancer	0.00083	0.0021	CcSEcCtD
Vidarabine—Asthenia—Methotrexate—muscle cancer	0.000809	0.00204	CcSEcCtD
Vidarabine—Urticaria—Doxorubicin—muscle cancer	0.000775	0.00196	CcSEcCtD
Vidarabine—Dizziness—Methotrexate—muscle cancer	0.000745	0.00188	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—MDM2—muscle cancer	0.00072	0.00331	CbGpPWpGaD
Vidarabine—Hypersensitivity—Doxorubicin—muscle cancer	0.000719	0.00182	CcSEcCtD
Vidarabine—Vomiting—Methotrexate—muscle cancer	0.000717	0.00181	CcSEcCtD
Vidarabine—Rash—Methotrexate—muscle cancer	0.000711	0.0018	CcSEcCtD
Vidarabine—Dermatitis—Methotrexate—muscle cancer	0.00071	0.0018	CcSEcCtD
Vidarabine—Headache—Methotrexate—muscle cancer	0.000706	0.00179	CcSEcCtD
Vidarabine—Asthenia—Doxorubicin—muscle cancer	0.0007	0.00177	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—PTCH1—muscle cancer	0.000687	0.00316	CbGpPWpGaD
Vidarabine—Nausea—Methotrexate—muscle cancer	0.00067	0.00169	CcSEcCtD
Vidarabine—Dizziness—Doxorubicin—muscle cancer	0.000645	0.00163	CcSEcCtD
Vidarabine—ADORA2A—GPCR downstream signaling—CNR1—muscle cancer	0.000638	0.00294	CbGpPWpGaD
Vidarabine—Vomiting—Doxorubicin—muscle cancer	0.000621	0.00157	CcSEcCtD
Vidarabine—Rash—Doxorubicin—muscle cancer	0.000615	0.00156	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—muscle cancer	0.000615	0.00155	CcSEcCtD
Vidarabine—Headache—Doxorubicin—muscle cancer	0.000611	0.00155	CcSEcCtD
Vidarabine—Nausea—Doxorubicin—muscle cancer	0.00058	0.00147	CcSEcCtD
Vidarabine—ADORA2A—Signaling by GPCR—CNR1—muscle cancer	0.000579	0.00267	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—muscle cancer	0.000547	0.00252	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTGS2—muscle cancer	0.000456	0.0021	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTCH1—muscle cancer	0.000406	0.00187	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FOXO4—muscle cancer	0.000349	0.0016	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CNR1—muscle cancer	0.000342	0.00158	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTGS2—muscle cancer	0.00031	0.00143	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF2—muscle cancer	0.00028	0.00129	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FOXO1—muscle cancer	0.000258	0.00119	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KIT—muscle cancer	0.000196	0.000903	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MDM2—muscle cancer	0.000155	0.000711	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFA—muscle cancer	0.000117	0.00054	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—muscle cancer	8.87e-05	0.000408	CbGpPWpGaD
